Year: 2022
Type: article
Abstract: Curcumin (CUR), a natural phenolic compound, has been increasingly investigated in several malignancies due to its safe profile and ability to affect a wide range of oncogenic targets. With the ability to affect metastasis, apoptosis, and angiogenesis in colorectal cancer (CRC) and its tolerability at high doses, CUR is an attractive target for study. However, poor bioavailability and unfavorable pharmacokinetics and pharmacodynamics have hampered CUR's efficacy in clinical trials. Development of its derivatives and alternative delivery methods have shown the potential to overcome its inherent bioavailability issues. Recent analyses of various derivatives and nanoparticle encapsulation of CUR have demonstrated increased effectiveness in CRC studies. A major advantage of CUR has been its synergistic effects when used in combination with various chemotherapeutic agents. CUR offers a unique treatment option in terms of patient safety and its ability to be used in combination with current treatments for CRC. Further development of its derivatives and alternative delivery options offer potential new avenues of treatment that could outperform previous efforts to establish CUR as a CRC therapy.
Source: Onco Therapeutics
Authors: Christoffer Lambring, Kelly Varga, Keriman Livingston, Nicholas Lorusso, Amil Dudhia, Riyaz Basha
Language: English
Subfield: Molecular Medicine
Domain: Life Sciences
Open Access status: green
Awards: 1/2 Langston University- UNTHSC Partnership for Cancer Research and Education, Texas Center for Minority Health, Education, Research and Outreach, AIM-AHEAD Coordinating Center - All Four Cores, HSC Scholars in Cancer Research, G7496696720, UNT Health Science Center IMSD, Texas Center for Minority Health, Education, Research and Outreach, 2/2 Langston University-UNTHSC Partnership for Cancer Research and Education, G9000292904, Texas Center for Health Disparities (TCHD)
OpenAlex ID: W4288785528